NuPathe announces encouraging results from Phase I migraine trial NuPathe's NP101 combines its SmartRelief proprietary iontophoretic transdermal technology with sumatriptan, the most widely prescribed treatment for acute migraine in the US and the active ingredient in Imitrex. The study was a Phase...
Merck Experimental Migraine Drug Proves Better Than Zomag In Late-Stage Study (FinancialWire) Merck & Co.'s (NYSE: MRK) experimental treatment for migraine headaches provided similar pain relief to AstraZeneca PLC's (NYSE: AZN) Zomig treatment in a late-stage study, but was better tolerated.Telcagepant works...
Merck Experimental Migraine Drug Proves Better Than Zomag In Late-Stage Study (FinancialWire) Merck & Co.'s (NYSE: MRK) experimental treatment for migraine headaches provided similar pain relief to AstraZeneca PLC's (NYSE: AZN) Zomig treatment in a late-stage study, but was better tolerated.Telcagepant works...
Merck Experimental Migraine Drug Proves Better Than Zomag In Late-Stage Study (financialwire.net via COMTEX) -- MRK | Quote | Chart | News | PowerRating -- June 30, 2008 (FinancialWire) Merck & Co.'s (NYSE: MRK | Quote | Chart | News | PowerRating) experimental treatment for migraine headaches provided similar...
Zogenix reports positive results from sumatriptan DosePro study The first clinical study evaluated the pharmacokinetics, bioequivalence and safety of needle-free sumatriptan DosePro, compared to a needle-based autoinjector, Imitrex STATdose used in the treatment of migraine.DosePro is a novel,...
A Drug to End Merck's Headache? Merck (NYSE: MRK) has given investors a lot of headaches lately.From Merck's and Schering-Plough's (NYSE: SGP) problems with Vytorin and Zetia to its own issues with the drug formally known as Cordaptive, Merck's investors have had good...
Zogenix Announces Clinical Study Results for sumatriptan DosePro(TM), a Novel Migraine Treatment Zogenix, Inc.('Zogenix'), a private, specialty pharmaceutical company, today announced that it will present successful results from two clinical studies of sumatriptan DosePro, a product in development for treatment of acute migraine and...
Zogenix Announces Clinical Study Results for sumatriptan DosePro(TM), a Novel Migraine Treatment Zogenix, Inc.('Zogenix'), a private, specialty pharmaceutical company, today announced that it will present successful results from two clinical studies of sumatriptan DosePro, a product in development for treatment of acute migraine and...
Zogenix Announces Clinical Study Results for sumatriptan DosePro(TM), a Novel Migraine Treatment - Zogenix, Inc.('Zogenix'), a private, specialty pharmaceutical company, today announced that it will present successful results from two clinical studies of sumatriptan DosePro, a product in development for treatment of acute migraine...
Merck migraine drug matches rival's medication NEW YORK -- Merck & Co's experimental treatment for migraine headaches provided similar pain relief to AstraZeneca PLC's Zomig treatment in a late-stage study, but was better tolerated, Merck said.Favourable phase 3 data for Merck's...
Zogenix Announces Clinical Study Results for sumatriptan DosePro(TM), a Novel Migraine Treatment , 7:00 AM EST News source: Business Wire Zogenix, Inc.('Zogenix'), a private, specialty pharmaceutical company, today announced that it will present successful results from two clinical studies of sumatriptan DosePro, a product in...
Merck migraine drug matches Zomig in study NEW YORK (Reuters) - Merck (nyse: MRK - news - people ) & Co's experimental treatment for migraine headaches provided similar pain relief to AstraZeneca PLC (nyse: AZN - news - people )'s Zomig treatment in a late-stage study, but was...
Indian generic companies may tread Ranbaxy path India's leading pharma firms such as Ranbaxy, Dr Reddy's (DRL), Sun Pharma and Lupin are all involved in various patent litigation's with global drug biggies like Pfizer, Eli Lilly, Glaxo, Wyeth, Novartis and AstraZeneca.Last year alone,...
GlaxoSmithKline and the IRS Finally Find Relief with Zantac Longstanding Dispute over Transfer Pricing Settled JUNE 2008 - When it comes to transfer pricing, even the most seasoned tax professionals can find themselves with a stomachache.Transfer pricing is at the heart of a long-running dispute...
Generic cos may tread Ranbaxy path MUMBAI: Ranbaxy Laboratories' patent settlement with Pfizer may set a trend, with more Indian generic firms likely to go for out-of-court settlements with their innovator counterparts.India's leading pharma firms such as Ranbaxy, Dr Reddy...
Indian generic companies may tread Ranbaxy path MUMBAI: Ranbaxy Laboratories' patent settlement with Pfizer may set a trend, with more Indian generic firms likely to go for out-of-court settlements with their innovator counterparts.Indias leading pharma firms such as Ranbaxy, Dr Reddys...
Spectrum receives $20 million cash payment from Par Pharmaceutical Sumatriptan injection is the generic form of GlaxoSmithKline's Imitrex injection, which is currently selling on the market and is indicated for the acute treatment of migraine attacks with or without aura and the acute treatment of...
US FDA approves Pozen's migraine drug Treximet Following years of regulatory hurdles, the FDA has approved Pozen's Treximet, which combines an anti-inflammatory with GlaxoSmithKline's Imitrex, for the acute treatment of migraine attacks with or without aura in adults.Pozen first...
FDA OKs New Migraine Drug Treximet -- The FDA has approved a new migraine drug called Treximet for the acute treatment of migraine attacks, with or without aura, in adults.Treximet is a combination of sumatriptan (the active ingredient in the migraine drug Imitrex) ...
Pozen-GSK migraine drug wins FDA approval Pozen has won approval from the U.S.Food and Drug Administration for the Treximet migraine drug it developed with GlaxoSmithKline, the company said late Tuesday.
The announcement brings vindication to Chapel Hill-based Pozen (NASDAQ...
Use of Rx to OTC Switch as Product Management Tactic Enjoys Comeback /PRNewswire/ -- There are 14 prescription drugs that exceeded $20 billion in sales in 2006, that may have the potential to reach the over-the-counter market in four years.Prescription to OTC switches were frequent in 2006 and 2007 and a...
